Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION (REVORUTION)

AstraZeneca

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00526721

NIS-CKR-CRE-2007/6

Details and patient eligibility

About

To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Enrollment: 1,482 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria

  1. Over 18 years of age
  2. Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20%

Exclusion criteria

1. Patients already taking other hyperlipidemic agents
2. Patients who do not fulfil the indication criteria for statin therapy
3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data